Abstract 1479P
Background
Refractory cancer pain (RCP) affects 10-20% of cancer patients, exhibiting limited response to standard opioids (OPI). Ketamine (KET), an anesthetic medication, has gained recent attention for its potential in managing RCP. This study aims to describe the consumption of rescue OPI before and after initiating KET, the rate of patients meeting a controlled pain criteria, and its safety profile.
Methods
A prospective observational study was conducted in three academic hospitals. Over an 18-month period, we included all cancer patients who initiated KET therapy based on the criteria of their treating medical team. The frequency of OPI rescues was recorded on days five (D-5) and two (D-2), and on days two (D+2) and five (D+5) pre and post KET initiation, respectively. Controlled pain criteria were defined as a 72-hour interval with no more than 3 OPI rescues per day, absence of breakthrough pain, and no escalation in OPI dosage. All adverse effects (AEs) were recorded in accordance with the CTCAE 5.0 guidelines.
Results
Fifty-two patients were included, and their characteristics are described in the table. The most common initiation dose of KET was 0.5 mg/kg/day orally (71.2%). Median oral morphine milligram equivalent (MME) at initiation of KET was 120mg. Overall survival from the onset of KET therapy was 43 days. Median daily OPI rescue was 3.90 on D-5 and 4.62 on D-2, decreasing to 2.79 on D+2 and 2.77 on D+5 (p=
Conclusions
A significant decrease in rescue opioids usage was observed after initiating ketamine. Over 60% of the patients met the criteria for controlled pain, with a favorable safety profile. Further comparative studies are required to better understand the role of ketamine in cancer pain.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Vall d'Hebron University Hospital.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1564P - Limited participation in breast cancer screening among low-SES women: A matter of engagement or of health literacy?
Presenter: Allegra Ferrari
Session: Poster session 10
1566P - Optimizing participation in lung cancer screening program: Results from the first round in ILYAD study in Lyon University Hospital
Presenter: Emmanuel Grolleau
Session: Poster session 10
1567P - Physicians' adenoma detection rate and the risk of colorectal cancer in sequential screening programs: An observational cohort study
Presenter: Li Xie
Session: Poster session 10
1568P - Challenges in pilot lung cancer screening in Vojvodina, Serbia
Presenter: Jelena Djekic Malbasa
Session: Poster session 10
1569P - Secondary delay in breast cancer diagnosis and role of rural medical practitioners: A cause and cure finding study
Presenter: Rahul Agarwal
Session: Poster session 10
1570P - Factors and impacts of delayed presentation for county-level patients with breast cancer in a real-life setting in China
Presenter: Yinghua Ji
Session: Poster session 10
1571P - The reasons that motivate a change of specialties among oncology residents
Presenter: Christophe Ducrocq
Session: Poster session 10
1572P - Factors associated with career choice in oncology among medical students
Presenter: Nicolas Penel
Session: Poster session 10
1573P - Global cancer statistics for adolescents and young adults: New estimates from GLOBOCAN 2022
Presenter: Wang-Zhong Li
Session: Poster session 10
Resources:
Abstract